EBMT  Publishes 2025 Clinical Practice Recommendations for Haematopoietic Cell Transplantation and CAR-T Therapy

Barcelona, Spain – 2 October 2025 – European Society for Blood and Marrow Transplantation (EBMT) has  released its ninth special report on indications for haematopoietic cell transplantation (HCT) and chimeric antigen receptor T-cell (CAR-T) therapy. The report provides updated guidance for clinicians treating haematological diseases, solid tumours, and immune disorders.

Over the past two decades, EBMT has refined its recommendations to align with evolving clinical and scientific developments. The 2025 report underscores the importance of harmonising practices across transplant centres to improve patient outcomes and facilitate meaningful data aggregation. It also highlights the growing role of innovative therapies, such as CAR-T and advanced therapy medicinal products (ATMPs), in transforming treatment paradigms.

The manuscript outlines available data, general guidance, and key references, complemented by disease-specific tables that provide concise recommendations for HCT and CAR-T indications based on disease status, donor availability, and level of evidence in both adult and paediatric populations. It also addresses advances in gene therapy, emphasises the importance of quality standards such as JACIE certification, and encourages comprehensive reporting to the EBMT Registry to strengthen real-world evidence and long-term outcome evaluation. A multidisciplinary approach is recommended to balance disease risk, procedural risks, and alternative strategies, with a focus on survival and quality of life.

“These recommendations aim to support clinicians in optimising treatment strategies across EBMT centres, ensuring that patients benefit from the most up-to-date advances in cellular and gene therapies,” said Raffaella Greco, co-lead author.

“Since the last edition, innovative cellular and gene therapies have entered clinical practice across several indications, significantly influencing decision-making. We strongly encourage every EBMT centre to download the updated recommendations and integrate them into daily practice to ensure consistency and the highest quality of care for patients.” added Annalisa Ruggeri, co-lead author.

For more information, read the full publication: https://www.nature.com/articles/s41409-025-02701-3

About EBMT:

The EBMT is a non-profit medical and scientific organisation established in 1974 which hosts a unique patient registry providing a pool of data to perform studies and assess new trends. We aim to be the connection between patients, researchers and other stakeholders to anticipate the future of cellular and stem cell-based therapies. Our community of healthcare professionals is focused on innovation, research and the advancement of these fields to save and improve the lives of patients with blood-related disorders. 

For more information, please visit www.ebmt.org.

Follow @TheEBMT on X, LinkedIn, Facebook and YouTube